The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy.
There are no risks for the patients, as this is a retrospective data collection.

开始日期2024-09-30

申办/合作机构

Fondazione San Raffaele del Monte Tabor-Milano

[+5]

NCT05776758 / Recruiting临床3期IIT

Neoadjuvant Chemotherapy Plus Cystectomy vs Cystectomy Alone for cT0 Muscle-invasive Bladder Cancer After Maximal TURBt: Multicentre Prospective Randomized Controlled Trial

This prospective randomized controlled trial (RCT) is designed to provide high level evidence describing the non-inferiority of radical cystectomy (RC) alone versus neoadjuvant chemotherapy (NAC) plus RC on survival outcomes of patients with a diagnostic transurethral resection of bladder tumor (TURBt) of non-metastatic muscle invasive bladder cancer (MIBC) (T2-T4 N0 M0) and non-radiologic or endoscopic residual tumor after a maximal TURBt (cT0). Our hypothesis is that performing NAC in the absence of residual disease, after a maximal TURBt, has no survival benefit over performing an early cystectomy. Since no downstaging could be achieved in patients with no residual tumor into the bladder, the benefits of neoadjuvant chemotherapy in this setting could be not significant and it might turn into unnecessary toxicity and a substantial delay to surgical treatment.

开始日期2024-04-01

申办/合作机构

Regina Elena Cancer Institute

NCT06439303 / RecruitingN/AIIT

Analysis and Evaluation of Smoking Treatment With Cytisine: Retrospective Observational Study

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

开始日期2024-03-20

申办/合作机构

Regina Elena Cancer Institute

100 项与 Regina Elena Cancer Institute 相关的临床结果

登录后查看更多信息

0 项与 Regina Elena Cancer Institute 相关的专利（医药）

登录后查看更多信息

2,807

项与 Regina Elena Cancer Institute 相关的文献（医药）

2024-11-01·Journal of Molecular Medicine

Retraction Note: Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells

作者: Spinella, Francesca ; Caprara, Valentina ; Cianfrocca, Roberta ; Di Castro, Valeriana ; Bagnato, Anna ; Rosanò, Laura ; Natali, Pier Giorgio

2024-10-01·Urologic Oncology: Seminars and Original Investigations

Characteristics, trends, and management of Penile cancer in the United States: A population-based study

Article

作者: Manfredi, Celeste ; Licari, Leslie Claire ; Autorino, Riccardo ; Leonardo, Costantino ; Franco, Antonio ; Ditonno, Francesco ; Coogan, Christopher L ; Perdona, Sisto ; De Nunzio, Cosimo ; Brassetti, Aldo ; Bologna, Eugenio ; Cherullo, Edward E

BACKGROUNDPenile cancer (PeCa) is a rare disease. HPV infection, smoking, phimosis, and lichen sclerosus represent well-known associated risk factors.OBJECTIVESPrimary aim of our study is to evaluate the incidence and risk factors of PeCa and to outline the adopted diagnostic and therapeutic approaches. Secondary aim is to investigate risk factors associated with aggressive disease and to identify the complications arising from its surgical treatment.MATERIALS AND METHODSWe conducted a retrospective analysis using the PearlDiver™ Mariner database, from January 1, 2011, to December 31, 2021, identifying all patients diagnosed with PeCa and PeIN, evaluating comorbidities, risk factors, and social and economic conditions. We evaluated the imaging modalities employed for staging as well as the treatment strategies. Finally, we evaluated the most frequent complications associated with inguinal lymphadenectomy (ILND).RESULTSDuring the study period, 17,494 patients were diagnosed with PeCa and 5,965 with penile intraepithelial neoplasia (PeIN). US was the most frequently utilized imaging modality, followed by PET and PET/CT. Use of CT and MRI was around 5%. Surgical treatment was the predominant strategy, utilized in 31.3% of PeCa and 22.9% of PeIN. Wide Local Excision/Glansectomy emerged as the most common surgical procedures. MLR analysis identified smoking as a risk factor for metastatic PeCa (OR; 95% CI = 1.49; 1.379-1.609), HPV infections were associated with a 35% decrease in risk (OR; 95% CI = 0.65; 0.562-0.744) (all P < 0.001). Lichen sclerosus and phimosis were associated with a doubled risk of demolitive surgery. Approximately 40% of patients experienced complications associated with ILND.CONCLUSIONDespite advances in PeCa management, there's no significant move toward more conservative treatments. Surgical treatments are still marked by high rates of complications, potentially affect the sexual and psychosocial health of patients. These issues may foster a tendency toward avoidance behaviors, contributing to a delayed clinical presentation and treatment.

2024-10-01·Endoscopy International Open

Efficacy of novel endoscopic hemostatic agent for bleeding control and prevention: Results from a prospective, multicenter national registry

作者: de Nucci, Germana ; Fabbri, Carlo ; Maiero, Stefania ; Facciorusso, Antonio ; Repici, Alessandro ; Manes, Gianpiero ; Panarese, Alba ; Sbrancia, Monica ; Andrisani, Gianluca ; Binda, Cecilia ; Hassan, Cesare ; Rizza, Stefano ; Soriani, Paola ; Da Rio, Leonardo ; Di Matteo, Francesco Maria ; Cannizzaro, Renato ; Staiano, Teresa ; Maselli, Roberta ; D'Abramo, Fulvio ; Manno, Mauro ; Stigliano, Vittoria ; Sacco, Marco

Abstract Background and study aims Topical hemostatic agents emerged as a new treatment modality for gastrointestinal bleeding. The aim of this study was to assess the safety and efficacy of PuraStat for control of active bleeding and for prevention of bleeding after different operative endoscopy procedures. Patients and methods A national, multicenter, observational registry was established to collect data from ten Italian centers from June 2021 to February 2023. Demographics, type of application (active gastrointestinal bleeding or prevention after endoscopic procedures, site, amount of gel used, completeness of coverage of the treated area), outcomes (rates of intraprocedural hemostasis and bleeding events during 30-day follow-up), and adverse events (AEs) were prospectively analyzed. Results Four hundred and one patients were treated for active gastrointestinal bleeding or as a preventive measure after different types of operative endoscopy procedures. Ninety-one treatments for active bleeding and 310 preventive applications were included. In 174 of 401 cases (43.4%), PuraStat was the primary treatment modality. Complete coverage was possible in 330 of 401 (82.3%) with difficulty in application in seven of 401 cases (1.7%). Hemostasis of active bleedings was achieved in 90 of 91 patients (98.9%). In 30-day follow-up 3.9% patients in whom PuraStat was used for prophylaxis had a bleeding event compared with 7.7% after hemostasis. No AEs related to the use of PuraStat were reported. Conclusions PuraStat is a safe and effective hemostat both for bleeding control and for bleeding prevention after different operative endoscopy procedures. Our results suggest that the possible applications for the use of PuraStat may be wider compared with current indications.

100 项与 Regina Elena Cancer Institute 相关的药物交易

登录后查看更多信息

100 项与 Regina Elena Cancer Institute 相关的转化医学

登录后查看更多信息